| Vol. 14.03 – 27 January, 2022 |
| |
|
|
| Scientists determined whether human chronic villi-mesenchymal stromal cells (hCV-MSCs) were ciliated and whether altered ciliation was responsible for defective hCV-MSCs in preeclamptic placentas, as the primary cilium was a hub for signal transduction, which was important for various cellular activities. [BMC Medicine] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors cross-compared transcriptomic and proteomic data and selected 26 candidate genes with the same expression trends in both omics analyses. [Stem Cell Reviews and Reports] |
|
|
|
| A novel protocol was developed to isolate and culture decidual natural killer cells cells from fresh, term placentas and complete hydatidiform moles. [Journal of Reproductive Immunology] |
|
|
|
| Researchers examined the impact of the reduced uterine perfusion pressure rat model of preeclampsia on the maternal cardiovascular system, placental and fetal heart metabolism. [Scientific Reports] |
|
|
|
| Trisomy 16 is the most common aneuploidy in first-trimester miscarriages. Scientists identified changes in DNA methylation in chorionic villi of miscarriages with trisomy 16. [Scientific Reports] |
|
|
|
| Scientists explored the effect of abnormally expressed long non-coding RNA ZEB2-AS1 on the occurrence of recurrent spontaneous abortion. [Reproductive Sciences] |
|
|
|
| Researchers determined whether metabolites from a retrospective collection of banked cord blood specimens could accurately estimate gestational age and validated these findings in cord blood samples from Busia, Uganda. [Journal of Perinatology] |
|
|
|
|
| The authors review currently available information on lead (Pb)-mediated alterations in the fetal epigenome is summarized. [Journal of Applied Toxicology] |
|
|
|
|
| Celularity Inc. announced the US FDA has granted Fast Track Designation for its genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-101, which is being developed in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients in first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. [Celularity, Inc.] |
|
|
|
|
| March 19 – 23, 2022 Prague, Czech Republic & Online |
|
|
|
|
|
| Penn State College of Medicine – Hershey, Pennsylvania, United States |
|
|
|
| Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| Fox Chase Cancer Center, Temple University – Philadelphia, Pennsylvania, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|